Pyruvate kinase isozymes and regulation There are four isoenzymes of - PowerPoint PPT Presentation

Nov 23, 2023 •729 likes •774 views

Pyruvate kinase isozymes and regulation There are four isoenzymes of PK: PKL (liver) and PKR (erythrocytes) are produced from PKLR gene PKM1 (muscle an brain) and PKM2 (fetal and most tissues) produced from PKM gene. The PKLR are

Pyruvate kinase isozymes and regulation There are four isoenzymes of PK: PKL (liver) and PKR (erythrocytes) are produced from PKLR gene PKM1 (muscle an brain) and PKM2 (fetal and most tissues) produced from PKM gene. The PKLR are allosterically regulated: inhibited by phosphorylation by protein kinase A, ATP, acetyl-CoA, alanine, and long-chain fatty acids activated by F1,6-BP. The liver enzyme is also controlled at the level of synthesis. Increased carbohydrate ingestion induces the synthesis of PK.
Fetal PK In erythrocytes, the fetal PK isozyme has much greater activity than the adult isozymes. Fetal erythrocytes have lower concentrations of glycolytic intermediates including 1,3BPG, (and 2,3BPG)

Recommend

PSYCHO-SOCIAL EFFECTS OF HAVING A DISEASE LIKE PYRUVATE KINASE DEFICIENCY A PATIENT PERSPECTIVE 6

PSYCHO-SOCIAL EFFECTS OF HAVING A DISEASE LIKE PYRUVATE KINASE DEFICIENCY A PATIENT PERSPECTIVE 6 th EUROPEAN SYMPOSIUM ON RARE ANAEMIAS 1 st Dutch-Belgian meeting for patients and health professionals 21 st - 22 nd November 2015 Amsterdam - The

488 views • 19 slides

Pyruvate Kinase Deficiency Natural History Study Rachael Grace, MD, MMSc On behalf of the PKD

Pyruvate Kinase Deficiency Natural History Study Rachael Grace, MD, MMSc On behalf of the PKD NHS Investigators Assistant Professor, Harvard Medical School Director, Hematology Clinic, Boston Childrens Hospital, MA, USA 6 th EUROPEAN

681 views • 24 slides

of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FT-4202, an Allosteric

Phase 1 Single and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, in Healthy and Sickle Cell Disease Subjects Theodosia A. Kalfa, MD,

507 views • 15 slides

Protein Kinase C- ( PKC- ) Inhibition: A Promise not yet Fulfilled Ruboxistaurin, an oral

Protein Kinase C- ( PKC- ) Inhibition: A Promise not yet Fulfilled Ruboxistaurin, an oral PKC- , was withdrawn on March 15, 2007 by Eli Lilly Dual Inhibition of Classical Protein Kinase C- and Protein Kinase C- Isoforms Protects

415 views • 13 slides

IMPROVED STUDIES ON MALIGNANCIES WITH A NOVEL PROLIFERATION BIOMARKER - Thymidine Kinase 1

IMPROVED STUDIES ON MALIGNANCIES WITH A NOVEL PROLIFERATION BIOMARKER - Thymidine Kinase 1 AROCELL TK 210 ELISA 1 AGENDA 1 Proliferation Biomarkers 2 Thymidine Kinase 1 as a Tumor Biomarker 3 Thymidine Kinase 1 in the Study of Hematological

500 views • 37 slides

Addressing Key Mechanisms of Tumor Drug Resistance July 2018 Kinase switch control inhibitors

Addressing Key Mechanisms of Tumor Drug Resistance July 2018 Kinase switch control inhibitors for tumor- targeted and immune-targeted cancer therapies Our Proprietary Kinase Switch Control Platform Kinase Switched Off Kinase Switched

401 views • 16 slides

Driver Kinase Fusions in Cancer TCGA 4 th Annual Scientific Symposium May 12 th , 2015 Nicolas

Driver Kinase Fusions in Cancer TCGA 4 th Annual Scientific Symposium May 12 th , 2015 Nicolas Stransky, PhD What are Kinase Fusions? KIF5B-RET Fusion Genomic instability, a hallmark of cancer, can result in chromosomal translocations or

212 views • 17 slides

EGF receptor transactivation is crucial for cholinergic MAP kinase signaling in human

1st Electronic Conference on Molecular Science EGF receptor transactivation is crucial for cholinergic MAP kinase signaling in human keratinocytes Wymke Ockenga , Sina Khne, Antje Banning and Ritva Tikkanen Institute of Biochemistry,

298 views • 14 slides

Abietane Diterpenoids from Plectranthus spp. as a potential new class of Protein Kinase C

Abietane Diterpenoids from Plectranthus spp. as a potential new class of Protein Kinase C Modulators Patrcia Rijo 1,2* , Vera M. S. Isca 1,2 , Epole Ntungwe 1 , Cludia Bessa 3 , Carlos A.M. Afonso 2 , Luclia Saraiva 3 1 Center for Research in

538 views • 22 slides

Pantothenate kinase isoforms as collateral lethality targets in Glioblastoma Multiforme NAME OF

Pantothenate kinase isoforms as collateral lethality targets in Glioblastoma Multiforme NAME OF STUDENT On-Topic Candidacy Exam Adviser: Dr. XXXXXX Concomitant l loss o of p passeng nger ge genes es o occur with genomic c de deletion

637 views • 38 slides

Elucidating cell-to-cell variability in phosphorylation of the ERK MAP kinase Sarah Filippi

Elucidating cell-to-cell variability in phosphorylation of the ERK MAP kinase Sarah Filippi Imperial College London Theoretical Systems Biology Group 20/02/2013 The ERK MAP pathway In eukaryotes Mitogen-activated protein (MAP) kinases

411 views • 29 slides

Substrate Enhancement Therapy With Deoxycytidine and Thymidine in Patients With Thymidine Kinase

Substrate Enhancement Therapy With Deoxycytidine and Thymidine in Patients With Thymidine Kinase 2 Deficiency UMDF Power Surge 2020 Virtual Conference Michio Hirano, Cristina Domnguez-Gonzlez, Carmen Paradas, Marcos Madruga, Andres

266 views • 13 slides

A First-in-class Phase 1 Dose-escalation Study of the Novel Oral ERK 1/2 Kinase Inhibitor BVD-523

A First-in-class Phase 1 Dose-escalation Study of the Novel Oral ERK 1/2 Kinase Inhibitor BVD-523 (ulixertinib) in Patients with Advanced Solid Tumors Jeffrey R. Infante, Filip Janku, Anthony W. Tolcher, Manish Patel, Ryan J. Sullivan, Keith T.

227 views • 21 slides

Progress on the co-crystallization of Thermoplasma acidophilum nucleoside kinase (TaNK) with

Progress on the co-crystallization of Thermoplasma acidophilum nucleoside kinase (TaNK) with substrates Jessica Yoo Columbus Lab CSS Symposium 1 Protein Misannotation High as for some protein families 1 80% Accuracy

170 views • 12 slides

LATITUDE-TIMI 60 L osm A pimod T o I nhibi T p38 MAP kinase as a therape U tic target and mo D ify

LATITUDE-TIMI 60 L osm A pimod T o I nhibi T p38 MAP kinase as a therape U tic target and mo D ify outcomes after an acute coronary syndrom E NCT02145468 (www.clinicaltrials.gov) Michelle L. ODonoghue, MD MPH On behalf of the LATITUDE-TIMI 60

510 views • 21 slides

ACALABRUTINIB IN MCL Simon Rule Professor of Clinical Haematology Consultant Haematologist

ACALABRUTINIB IN MCL Simon Rule Professor of Clinical Haematology Consultant Haematologist Derriford Hospital and Peninsula Medical School Plymouth UK BRUTON S TYROSINE KINASE (BTK): A CRITICAL KINASE FOR LYMPHOMA CELL SURVIVAL AND

878 views • 24 slides

Inhibition of Fyn Kinase for Disease- Modifying Therapy of Alzheimers Disease Stephen M.

Inhibition of Fyn Kinase for Disease- Modifying Therapy of Alzheimers Disease Stephen M. Strittmatter, M.D., Ph.D. Vince Coates Professor Neurology Director, Cellular Neuroscience, Neurodegeneration & Repair Director, Memory Disorders

784 views • 55 slides

Targeting the ATR Kinase in Cancer Therapy 2017 Chabner Colloquium October 30, 2017 Lee Zou MGH

Targeting the ATR Kinase in Cancer Therapy 2017 Chabner Colloquium October 30, 2017 Lee Zou MGH Cancer Center Harvard Medical School Disclosure Consultant/advisory role: Loxo Oncology DNA Damage and Replication Stress Response Pathways

1.04k views • 81 slides

human protein kinase CK2 Christian Nienberg 1, *, Anika Retterath 1 , Kira Sophie Becher 2 ,

Click chemistry for advanced drug discovery applications of human protein kinase CK2 Christian Nienberg 1, *, Anika Retterath 1 , Kira Sophie Becher 2 , Henning D. Mootz 2 and Joachim Jose 1 1 Institut fr Pharmazeutische und Medizinische Chemie,

619 views • 15 slides

Tyrosine Kinase Receptor Priscila DA S ILVA F IGUEIREDO C ELESTINO 1,2 , Elodie L AINE 1 , Pedro

Impact of the D802V Mutation on the Structure and Dynamics of the CSF-1R Tyrosine Kinase Receptor Priscila DA S ILVA F IGUEIREDO C ELESTINO 1,2 , Elodie L AINE 1 , Pedro Geraldo P ASCUTTI 2 and Luba T CHERTANOV 1 1 ByMoDyM, LBPA, CNRS, cole

317 views • 20 slides

EH Regulation EH Regulation EH Regulation ENV H 471 Winter 2004 Room T-498 HSC Charles D.

Lesson 1. Law and Environmental Health January 7, 2003 EH Regulation EH Regulation EH Regulation ENV H 471 Winter 2004 Room T-498 HSC Charles D. (Chuck) Treser Department of Environmental & Occupational Health Sciences University

345 views • 6 slides

Epstein-Barr Virus BGLF4 Kinase Induces Disassembly of the Nuclear Lamina to Facilitate Virion

Epstein-Barr Virus BGLF4 Kinase Induces Disassembly of the Nuclear Lamina to Facilitate Virion Production Chung-Pei Lee et al . Journal of Virology, 82 :11913-11926, 2008. Speaker: Shiang-Yuan Hsieh Advisor: Li-Kwan Chang, PhD Date: 2008.11.25

684 views • 33 slides

Prediction of Human Protein Kinase Substrate Specificities Javad Safaei 1 , Jan Manuch 1 , Arvind

Prediction of Human Protein Kinase Substrate Specificities Javad Safaei 1 , Jan Manuch 1 , Arvind Gupta 1 , Ladislav Stacho 2 , Steven Pelech 3 1. UBC, Department of Computer Science 2. SFU, Department of Mathematics 3. UBC, Department of

497 views • 17 slides

DUVELISIB (IPI-145) Phosphoinositide-3-kinase- d , g Inhibitor Pierluigi Porcu, M.D. Professor of

DUVELISIB (IPI-145) Phosphoinositide-3-kinase- d , g Inhibitor Pierluigi Porcu, M.D. Professor of Internal Medicine Division of Hematology, and Comprehensive Cancer Center The Ohio State University The Ohio State University Comprehensive Cancer

426 views • 19 slides